Buy (150 RUB)
|Generate QR code
Open Access
Subscription or Fee Access
Cell technologies as a platform for personalized therapy: global challenges in oncology
https://doi.org/10.21508/1027-4065-2022-67-3-5-10
Abstract
The incidence of various types of cancer is steadily increasing. It is necessary to correctly analyze and interpret statistical data, given that the quality of medical care at all its stages is characterized not by the level of morbidity, but by the mortality rate. The leading centers of the Russian Federation can apply almost all the therapy methods to treat patients. At the same time, one of the limiting factors for increasing the survival rate is the detection of diseases mainly at the late stages, which dictates the need to increase oncological alertness and the widespread introduction of early screening diagnostics into healthcare practice. The development of many new targeted drugs has led to the fact that only a few have been shown to be effective in the treatment of only certain types of tumors. The development of bone marrow transplantation contributed to the development of other directions in medicine, which proved that the hematopoietic stem cell is a platform for personalized therapy for many diseases. The article describes the problems of cell therapy implementation in the treatment of cancer patients.
About the Authors
M. Yu. Rykov
Tver State Medical University;
N.A. Semashko National Research Institute of Public Health
Russian Federation
Russian Federation
Tver
G. L. Mentkevich
Tver State Medical University
Russian Federation
Russian Federation
Tver
I. S. Dolgopolov
Tver State Medical University
Russian Federation
Russian Federation
Tver
References
1. Dolgopolov I.C., Chkadua G.Z. Immunotherapy and Immunoprophylaxis of Certain Cancers: A Paradigm Shift. Onkopediatriya 2018; 5(1): 70–75. (in Russ.) DOI: 10.15690/onco.v5i1.1867
2. Robert C., Thomas L., Bondarenko I., O’Day S., Weber J., Garbe Claus. et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364(26): 2517–2526. DOI: 10.1056/NEJMoa1104621
3. Middleton M.R., Grob J.J., Aaronson N., Fierlbeck G., Tilgen W., Seiter S. et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18(1): 158–166. DOI: 10.1200/JCO.2000.18.1.158
4. Falkson C.I., Ibrahim J., Kirkwood J.M., Coates A.S., Atkins M.B., Blum R.H. et al. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group Study. J Clin Oncol 1998; 16(5): 1743–1751. DOI: 10.1200/JCO.1998.16.5.1743
5. Rusthoven J.J., Quirt I.C., Iscoe N.A., McCulloch P.B., James K.W., Lohmannet R.C. et al. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. J Clin Oncol 1996; 14(7): 2083–2090. DOI: 10.1200/JCO.1996.14.7.2083
6. Govindan R., Szczesna A., Ahn M.J., Schneider C.-P., Mella P.F.G., Barlesi F. et al. Phase III trial of ipilimumab combined with paclitaxel and carboplatin in advanced squamous non-small-cell lung cancer. J Clin Oncol 2017; 35(30): 3449–3457. DOI: 10.1200/JCO.2016.71.7629
7. Rosenberg S., Yang J., Sherry R., Kammula U.S., Hughes M.S., Phan G.Q. et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011; 17(13): 4550–4557. DOI: 10.1158/1078–0432.CCR-11–0116
8. Rykov M.Yu., Manerova O.A., Turabov I.A., Kozlov V.V., Reshetnikov V.A. The role of the pediatrician in the early diagnosis of malignant neoplasms in children. Rossiyskiy Vestnik Perinatologii i Pediatrii 2020; 65(1): 94–99. (in Russ.) DOI: 10.21508/1027–4065–2020–65–1–94–99
9. Rykov M.Yu., Manerova O.A., Turabov I.A., Kozlov V.V., Reshetnikov V.A. Algorithm for determining the feasibility of referring a patient for consultation with pediatric oncologist: results of implementation. Rossiyskiy Vestnik Perinatologii i Pediatrii 2019; 64(6): 84–88. (in Russ.) DOI: 10.21508/1027–4065–2019–64–6–84–88
10. Wolchok J.D., Kluger H., Callahan M.K., Postow M.A., Rizvi N.A., Lesokhin A.M. et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369(2): 122–133. DOI: 10.1056/NEJMoa1302369
11. Sakai K., Shimodaira S., Maejima S., Udagawa N., Sano K., Higuchi Y. et al. Dendritic cell-based immunotherapy targeting Wilms’ tumor 1 in patients with recurrent malignant glioma. J Neurosurg 2015; 123(4): 989–997. DOI: 10.3171/2015.1.JNS141554
12. Vik-Mo E.O., Nyakas M., Mikkelsen B.V., Moe M.C., Due-Tønnesen P., Suso E.M. et al. Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendriticcells in patients with glioblastoma. Cancer Immunol Immunother 2013; 62(9): 1499–1509. DOI: 10.1007/s00262-013–1453–3
13. Dolgopolov I.C., Chkadua G.Z., Mentkevich G.L. Does immunotherapy play role in the treatment of pediatric cancer: some clinical observations. Immunologiya gemopoeza 2015; 13(1): 63–78. (in Russ).
14. Mentkevich G.L. To the 30th anniversary of the first children’s department of bone marrow transplantation in Russia. Rossiyskiy Vestnik Perinatologii i Pediatrii 2021; 66(5): 7–9. (in Russ.) DOI: 10.21508/1027–4065–2021–66–5–7–9
15. Petenko N.N., Mikhailova I.N., Chkadua G.Z. Dendritic cell vaccine therapy of cutaneous melanoma after the radical surgery. Sarkomy kostei, myagkikh tkanei i opukholi kozhi 2015; 1: 43–49. (in Russ).
16. Barinsky I.F., Makhmudov F.R. Inactivated vaccine against herpes simplex viruses of the 1st and 2nd type as a means of effective immunoprophylaxis of recurrent genital herpes. Questions of virology.2010; 1: 35-40 (in Russ) http://www.fesmu.ru/elib/Article.aspx?id=217773
Review
For citations:
Rykov M.Yu., Mentkevich G.L., Dolgopolov I.S. Cell technologies as a platform for personalized therapy: global challenges in oncology. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics). 2022;67(3):5-10. (In Russ.) https://doi.org/10.21508/1027-4065-2022-67-3-5-10
Views:
467
Email this article 